GC1118, a Novel Anti-Egfr Antibody, Has Potent KRAS Mutation-Independent Antitumor Activity Compared With Cetuximab in Gastric Cancer

Gastric Cancer - Germany
doi 10.1007/s10120-019-00943-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

P16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients With Metastatic Colorectal Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2016English

A Novel Histone Deacetylase Inhibitor, CKD5, Has Potent Anti-Cancer Effects in Glioblastoma

Oncotarget
Oncology
2016English

The Anti-erbB3 Antibody MM-121/SAR256212 in Combination With Trastuzumab Exerts Potent Antitumor Activity Against Trastuzumab-Resistant Breast Cancer Cells

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2013English

A Small Molecule Approach to Degrade RAS With EGFR Repression Is a Potential Therapy for KRAS Mutation-Driven Colorectal Cancer Resistance to Cetuximab

Experimental and Molecular Medicine
BiochemistryMedicineClinical BiochemistryMolecular BiologyMolecular Medicine
2018English

BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

A Novel Anti‑EGFR Monoclonal Antibody (EMab‑17) Exerts Antitumor Activity Against Oral Squamous Cell Carcinomas via Antibody‑dependent Cellular Cytotoxicity and Complement‑dependent Cytotoxicity

Oncology Letters
Cancer ResearchOncology
2020English

A Novel Multifunctional Anti-Cea-Il15 Molecule Displays Potent Antitumor Activities

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Discovery of ABBV-4083, a Novel Analog of Tylosin a That Has Potent Anti-Wolbachia and Anti-Filarial Activity

PLoS Neglected Tropical Diseases
PharmacologyPublic HealthEnvironmentalToxicologyInfectious DiseasesPharmaceuticsOccupational Health
2019English

Antitumor Activity of Sorafenib Plus CDK4/6 Inhibitor in Pancreatic Patient Derived Cell With KRAS Mutation

Journal of Cancer
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy